Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
暂无分享,去创建一个
S. Nakamura | H Yoshida | M Bogaki | M Nakamura | S Nakamura | H. Yoshida | M. Nakamura | M. Bogaki | M. Nakamura | Shinichi Nakamura
[1] A. Wyke,et al. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones , 1989, Antimicrobial Agents and Chemotherapy.
[2] D. Holmes,et al. A rapid boiling method for the preparation of bacterial plasmids. , 1981, Analytical biochemistry.
[3] Jeffrey H. Miller. Experiments in molecular genetics , 1972 .
[4] J. Matsumoto,et al. Pyrido(2,3-d)pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids and their derivatives. , 1975, Journal of medicinal chemistry.
[5] S. Inoue,et al. New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity , 1981, Journal of bacteriology.
[6] S. Nakamura,et al. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli , 1989, Antimicrobial Agents and Chemotherapy.
[7] J. Wang,et al. Mapping the active site tyrosine of Escherichia coli DNA gyrase. , 1987, The Journal of biological chemistry.
[8] D. Kaminsky,et al. Quinolone antibacterial agents. Oxolinic acid and related compounds. , 1968, Journal of medicinal chemistry.
[9] Mika Nakamura. gyrAandgyrBMutations inQuinolone-Resistant Strains ofEscherichia coli , 1989 .
[10] A. Wyke,et al. Cloning andCharacterization ofaDNA Gyrase A Genefrom Escherichia coli ThatConfers Clinical Resistance to4-Quinolones , 1989 .
[11] M. Gellert,et al. DNA gyrase: subunit structure and ATPase activity of the purified enzyme. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[12] D. Kvam,et al. Bioevaluation of the Antibacterial Flumequine for Urinary Tract Use , 1976, Antimicrobial Agents and Chemotherapy.
[13] W. Kohlbrenner,et al. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. , 1989, The Journal of biological chemistry.
[14] W. Boll,et al. Hybrid plasmids containing an active thymidine kinase gene of Herpes simplex virus 1. , 1979, Nucleic acids research.
[15] K. R. Woods,et al. Prediction of protein antigenic determinants from amino acid sequences. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Y. Chou,et al. Prediction of the secondary structure of proteins from their amino acid sequence. , 2006 .
[17] S. Inoue,et al. Mode of Incomplete Cross-Resistance Among Pipemidic, Piromidic, and Nalidixic Acids , 1978, Antimicrobial Agents and Chemotherapy.
[18] J. Messing. [2] New M13 vectors for cloning , 1983 .
[19] J. Matsumoto,et al. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. , 1990, Journal of medicinal chemistry.
[20] M. Gellert,et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[21] Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents. , 1986, Journal of medicinal chemistry.
[22] G. Y. Lesher,et al. 1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. , 1962, Journal of medicinal and pharmaceutical chemistry.
[23] J. Messing. New M13 vectors for cloning. , 1983, Methods in enzymology.
[24] K. Mizuuchi,et al. Nalidixic acidresistance: Asecond genetic character involved inDNA gyrase activity , 1977 .